Wegovy Pills Cost in 2026: Oral Semaglutide Prices, Doses & Savings

Current official Wegovy tablet offers

The official Wegovy savings page reviewed August 2, 2026 listed $149 for one month of 1.5 mg tablets. It listed $149 for one month of 4 mg tablets through August 31, 2026, followed by $199 per month for 4 mg. One month is defined in the offer terms as one bottle of 30 tablets. Eligibility and restrictions apply, and Novo Nordisk says it may modify or cancel the program at any time.

The figures are manufacturer offer terms, not a universal retail price, insurance benefit, or guarantee of what every patient will pay. The same official page did not state a self-pay offer price for the 9 mg or 25 mg tablet doses in the terms captured for this review. That scoped finding means only that the amounts were not stated in the reviewed terms. It does not establish that no price exists elsewhere, and the 1.5 mg or 4 mg figures should not be extrapolated to those strengths.

For eligible commercially insured patients, the reviewed official page says patients may pay as little as $25 per month, subject to a maximum savings of $100 per month. Government beneficiaries are excluded, other restrictions apply, and “as little as” is not a guarantee. A current eligibility result and final pharmacy amount are still needed before treating the advertised floor as the amount due.

Read each amount together with its lane: self-pay or commercial insurance, exact tablet strength, one 30-tablet bottle, checked date, eligibility conditions, savings cap when applicable, and the manufacturer’s right to modify or cancel the program. Separating these fields preserves what the official terms establish without turning a conditional offer into a general price promise.

Why the amount may differ

A quoted manufacturer offer is only one part of the cost picture. The amount at checkout may depend on the tablet strength and point in the FDA-labeled escalation schedule, whether the patient qualifies for the current manufacturer offer, commercial insurance coverage, deductible, coinsurance, formulary rules, whether the plan requires prior authorization, the dispensing pharmacy, any fulfillment fees, and changes to offer terms after this article’s checked date.

Because the 4 mg offer has a dated change on August 31, 2026, any page that repeats the $149 amount after that date should be rechecked before relying on it. The checked date identifies when the cited page supported the statement; it does not freeze future terms. The official page and dispensing pharmacy are the appropriate places to verify a current amount.

A useful price record keeps the dosage form and strength beside the quote. It also keeps the offer type, one-month definition, eligibility restrictions, cap, deadline, and checked date beside the amount. Leaving out those qualifiers can make a source-accurate number misleading. This article therefore reports only the specific tablet terms the reviewed official page stated and leaves the 9 mg and 25 mg self-pay amounts as not stated in those terms.

What Wegovy tablets are

Wegovy tablets are FDA-approved, once-daily prescription tablets containing semaglutide. The FDA-approved tablet strengths are 1.5 mg, 4 mg, 9 mg, and 25 mg. The manufacturer describes the Wegovy pill as a once-daily prescription GLP-1 medication containing semaglutide. This identity and dosage-form summary comes from the current FDA prescribing information and the manufacturer’s official pill overview.

The current FDA prescribing information says Wegovy tablets are used with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight and at least one weight-related condition. The label also includes a cardiovascular-risk-reduction indication for certain adults with established cardiovascular disease and obesity or overweight. Those population qualifiers are part of the label summary.

FDA approval does not make Wegovy an over-the-counter weight-loss product. Wegovy is available only by prescription, and a licensed clinician should determine whether it is appropriate for an individual. This page reports source-bound product, schedule, administration, safety, and offer facts; it does not make an individual treatment recommendation or predict whether a prescription will be issued.

FDA-approved tablet strengths and schedule

The FDA lists four Wegovy tablet strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. The labeled adult tablet schedule increases every 30 days: 1.5 mg once daily for days 1 through 30, 4 mg once daily for days 31 through 60, 9 mg once daily for days 61 through 90, and 25 mg once daily from day 91 onward.

The FDA says to start with 1.5 mg once daily for 30 days and identifies 25 mg once daily as the recommended maintenance dosage for adult weight reduction and cardiovascular-risk reduction. The schedule is a summary of the current label, not a personal dosing recommendation. A prescriber should give patient-specific instructions, including what to do if tolerability, other medicines, or health conditions affect treatment.

The dose schedule should not be used to infer price. The reviewed official offer stated self-pay amounts for 1.5 mg and 4 mg only. The captured terms did not state a self-pay amount for 9 mg or 25 mg. The presence of those strengths in the label establishes approved strengths and schedule, not a commercial amount for every bottle.

How the tablet is taken

According to the FDA prescribing information, Wegovy tablets should be taken once daily on an empty stomach in the morning, with water up to 4 ounces. The tablet should be swallowed whole, not split, crushed, chewed, or dissolved. After taking a tablet, the label says to wait at least 30 minutes before eating food, drinking beverages, or taking other oral medicines.

These administration statements summarize the label and are not personalized instructions. Administration matters because it can affect absorption, but a price article cannot determine what an individual should do with timing, tolerability, a missed dose, another medicine, or a health condition. Patients should follow the prescription label and their clinician’s instructions rather than changing timing or dose based on cost information.

Tablet cost versus injection cost

Wegovy tablets and Wegovy injections are different dosage forms with different strengths and administration schedules. Their manufacturer offers are also presented differently. The official page reviewed for this article listed tablet self-pay terms for 1.5 mg and 4 mg. It separately listed introductory and ongoing amounts for injection pens.

Injection pen prices should not be copied into a tablet-cost table, and the tablet offer should not be used to predict the price of an injection dose. When comparing forms, use the current price tied to the exact prescribed dosage form and strength. Clinical suitability is a separate decision for a licensed prescriber, and this article neither compares efficacy nor recommends one form over another.

A like-for-like check starts by confirming whether the prescription is for a tablet or injection, then recording the exact strength and quantity. It keeps the current official offer and final pharmacy amount attached to that exact product. This prevents a tablet amount, injection amount, introductory term, or recurring term from being presented as if it applied to a different transaction.

A five-step cost check before filling a prescription

First, confirm the exact dosage form and strength. Ask whether the prescription is for tablets or injection and which strength will be dispensed. Second, open the current official Wegovy price page because offer terms may change after this article’s checked date. Third, check eligibility before assuming an offer applies; the commercial-insurance offer excludes government beneficiaries and has a monthly savings cap.

Fourth, ask the insurance plan about coverage. Verify formulary status, prior authorization, deductible, and coinsurance for the exact product. Fifth, confirm the final amount with the pharmacy. The checkout amount, rather than an undated search result, is the number that matters. These steps organize a price check and do not determine coverage, eligibility, medical suitability, or a treatment choice.

Save the date and exact wording used for the price check. A dated manufacturer figure can be useful without being universal or permanent. If the strength, dosage form, insurance lane, eligibility, offer window, or pharmacy changes, recheck the amount rather than carrying an earlier figure forward. For the reviewed terms, keep the August 31, 2026 transition attached to the 4 mg $149 amount.

Safety and prescription-only boundary

The FDA prescribing information for Wegovy carries a boxed warning about the risk of thyroid C-cell tumors. Wegovy is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. The label also lists known hypersensitivity to semaglutide or any excipient in Wegovy tablets or injection as a contraindication.

The label says concomitant use of Wegovy tablets or injection with another semaglutide-containing product or another GLP-1 receptor agonist is not recommended. This statement preserves the label’s limitation-of-use boundary. It is not a medicine-reconciliation service and does not determine what any individual should start, stop, combine, or change.

This is not a complete safety summary. Read the current prescribing information and discuss risks, other medicines, pregnancy plans, symptoms, and medical history with a licensed clinician. The page does not promise efficacy, expected weight loss, comparative safety, suitability, availability, coverage, savings, or an individual outcome.

How to keep this price check current

Recheck the official sources when the dated 4 mg offer reaches August 31, 2026, when Novo Nordisk changes or cancels its savings terms, when FDA prescribing information changes, or when a new official price is published for the 9 mg or 25 mg tablets. A revision should preserve the same boundaries: exact dosage form and strength, offer lane, checked date, eligibility and cap language, and a clear distinction between a source’s silence and a universal claim.

The three external links on this page are citations to the current 2026 FDA prescribing information, the official Wegovy cost page reviewed August 2, 2026, and the manufacturer’s official Wegovy pill overview. Related Clinic Scout links provide context about manufacturer self-pay terms, savings-card conditions, and the separate safety evidence guide. They are informational internal links, not affiliate, checkout, contact, or provider-recommendation links.

This article answers a bounded question: what the reviewed official sources said about oral Wegovy strengths, labeled use and administration, key safety boundaries, and current dated offers. It does not turn a manufacturer offer into a retail-price guarantee, state an unsupported 9 mg or 25 mg self-pay amount, interchange tablet and injection prices, give personalized dosing, or guarantee efficacy or savings.